Microablative Fractional Radiofrequency: A Breakthrough Non-Hormonal Option for Menopausal Genitourinary Health

What Are the Promising Advances in Non-hormonal GSM Therapy?

Microablative Fractional Radiofrequency Shows Promising Results for Genitourinary Syndrome of Menopause in Clinical Trial

A pilot randomized clinical trial has demonstrated that microablative fractional radiofrequency (MFR) therapy may offer an effective non-hormonal alternative for treating genitourinary syndrome of menopause (GSM), with results comparable to standard estriol treatment but with potentially fewer side effects. The study, conducted at Antonio Pedro University Hospital in Brazil, found that MFR was particularly effective at promoting beneficial Lactobacillus colonization while avoiding the increased Candida risk associated with hormonal treatments.

How Was the Clinical Trial Designed and What Were Its Key Findings?

The double-blind, placebo-controlled study involved 30 postmenopausal women with GSM symptoms who were randomized to receive either MFR therapy or topical estriol treatment over a three-month period. The research team, faced with recruitment challenges during the COVID-19 pandemic, initially calculated a required sample size of 64 participants but proceeded with the smaller cohort due to reduced patient flow to the hospital during this period.

While both treatments demonstrated efficacy in improving vaginal pH levels, the MFR group showed a particularly noteworthy increase in beneficial vaginal microbiota. Specifically, 66.7% of women in the MFR group exhibited type I microbiota (exclusive Lactobacillus presence) post-treatment compared to only 26.7% in the estriol group. "The significant increase in Lactobacillus demonstrates that MFR therapy beneficially restores the vaginal mucosa for the vaginal microbiome," the researchers noted in their findings.

Another significant finding was that women in the estriol group experienced a 33.3% increase in vaginal Candida colonization after treatment, a side effect not observed in the MFR group. This suggests MFR may offer a safety advantage for women concerned about fungal infections or those with recurrent vulvovaginal candidiasis.

What Technology Drives Microablative Radiofrequency Therapy?

The treatment protocol utilized the Wavetronic 6000–ACEL 1462 Touch device with a Linly vaginal fractional electrode containing 64 micro-needles. The technology works by stimulating neocollagenesis, neoelastogenesis, and neovascularization through fibroelastic stimulation, ultimately addressing the underlying tissue changes associated with estrogen deficiency in menopause.

Why Is Genitourinary Syndrome of Menopause a Persistent Challenge?

GSM affects up to 84% of menopausal women and, unlike hot flashes and other menopausal symptoms that typically improve over time, GSM is a chronic condition that progressively worsens without treatment. Current gold-standard treatment involves topical estrogen therapy, which is contraindicated in some patients, including those with a history of breast cancer or thromboembolic disorders.

What Insights Emerge from the Study? Limitations and Expert Opinions

The findings align with previous studies suggesting energy-based therapies like MFR could provide an important alternative for women who cannot or prefer not to use hormonal treatments. However, the researchers acknowledged several limitations, including the small sample size, heterogeneous duration of menopause among participants (ranging from 2 to 30 years), and the relatively short follow-up period.

"Although there was an improvement in the analyzed parameters of the vaginal microbiota with the MFR intervention, it did not show superiority over the use of topical estriol in improving the vaginal microbiota," the researchers concluded. "Therefore, there is a need to increase the number of participants and long-term follow-up to improve our findings and a possible recommendation in clinical practice."

How Was Vaginal Health Evaluated in the Study?

The study evaluated several parameters including pH changes, presence of Lactobacillus, coccobacilli, cocci, and Candida, as well as analyzing the number of basal and parabasal cells. Both treatment groups showed significant improvements in pH values, with 60% of the estriol group and 46.7% of the MFR group demonstrating pH improvement. Notably, the MFR group showed a higher proportion of women with exclusively Lactobacillus-dominated microbiota after treatment, suggesting a potentially superior effect on restoring healthy vaginal flora.

Investigators used the Vaginal Health Index Score (VHIS) to evaluate parameters such as elasticity, pH, fluid volume, integrity, and hydration of the vaginal wall. This index is particularly relevant as scores below 15 are diagnostic for vulvovaginal atrophy, a key component of GSM.

How Is the Market Shaping the Future of GSM Treatments?

The market for non-hormonal GSM treatments has been expanding as the population ages and awareness of women's postmenopausal health issues increases. Energy-based treatments like MFR, laser therapy, and radiofrequency represent an estimated $8 billion global market opportunity, with annual growth projections exceeding 8% through 2030.

Industry Context: This study comes amid growing interest in alternative treatments for menopausal symptoms, particularly as more women seek non-hormonal options. While energy-based devices for GSM have faced regulatory scrutiny in some markets, the scientific evidence supporting their efficacy continues to build. The findings contribute to a broader industry trend toward personalized menopausal care, where treatment options are tailored to individual patient needs, preferences, and contraindications rather than a one-size-fits-all approach.

Summary

A pilot randomized clinical trial conducted at Antonio Pedro University Hospital in Brazil has demonstrated that microablative fractional radiofrequency therapy may offer an effective non-hormonal alternative for treating genitourinary syndrome of menopause, with results comparable to standard estriol treatment. The double-blind, placebo-controlled study involved 30 postmenopausal women and found that microablative fractional radiofrequency was particularly effective at promoting beneficial Lactobacillus colonization, with 66.7% of treated women exhibiting exclusive Lactobacillus presence compared to only 26.7% in the estriol group. Notably, women receiving estriol experienced a 33.3% increase in vaginal Candida colonization, a side effect not observed in the microablative fractional radiofrequency group. The treatment utilizes technology that stimulates neocollagenesis, neoelastogenesis, and neovascularization to address tissue changes associated with estrogen deficiency. While both treatments improved vaginal pH levels, researchers acknowledged limitations including the small sample size and relatively short follow-up period, emphasizing the need for larger studies with long-term follow-up before clinical practice recommendations can be made. The findings contribute to the expanding market for non-hormonal genitourinary syndrome of menopause treatments, estimated at $8 billion globally with projected annual growth exceeding 8% through 2030, addressing a chronic condition that affects up to 84% of menopausal women.